Prasco will begin distribution of both products upon the first ANDA entrant into the market. Prasco will market all six strengths of Olanzapine Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg. Olanzapine Orally Disintegrating Tablets will be available in 5 mg, 10 mg, 15 mg, and 20 mg strengths. The financial terms of the agreement were not disclosed.
"Prasco's passion to bring high quality, low cost prescription drugs to consumers continues to expand," said Prasco Chief Executive Officer E. Thomas Arington. "We are especially excited to welcome Eli Lilly and Company to our Prasco family of partners."
Prasco is established as the Authorized Generics company, having brought more Authorized Generics to market than any other company by offering generic products that are identical to the Brand product. "Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the Olanzapine launch through our new Lilly relationship," Arington concluded.
Olanzapine Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA. Olanzapine Orally Disintegrating Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA ZYDIS.
For additional information about ZYPREXA and ZYPREXA ZYDIS, please see Full Prescribing Information including Box Warning here and Medication Guide here.
Companies in this press-release
